MMD gene

Known as: MMA, PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 11, MONOCYTE-TO-MACROPHAGE DIFFERENTIATION-ASSOCIATED PROTEIN 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Moyamoya disease (MMD) shows progressive cerebral angiopathy characterized by bilateral internal carotid artery stenosis and… (More)
  • figure 1
  • figure 2
  • table 2
  • table 3
  • figure 3
Is this relevant?
2010
2010
BACKGROUND AND PURPOSE To investigate the association between thyroid autoantibodies and moyamoya disease (MMD) in patients with… (More)
  • table 2
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVE Moyamoya disease (MMD) is a cerebrovascular occlusive disease of the bilateral internal carotid arteries that causes a… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2010
2010
BACKGROUND AND PURPOSE Pharmacological analysis of synergism or functional antagonism between different receptors commonly… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
BACKGROUND Methylmalonic acid (MMA) in plasma or serum is widely used for assessment of vitamin B(12) status. However, data are… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
Cobalamin nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene MUT… (More)
Is this relevant?
2006
2006
PURPOSE To determine whether sentinel lymph node (LN) sampling (SLNS) could reduce the number of nodes required to characterize… (More)
Is this relevant?
2005
2005
Serum concentrations of homocysteine (Hcy) and methylmalonic acid (MMA) become increased in B12-deficient subjects and are… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE The prognosis for moyamoya disease (MMD) among young patients is known to be worse than that among older patients. The… (More)
Is this relevant?